IK channel activation increases tumor growth and induces differential behavioral responses in two breast epithelial cell lines — Amy E. Thurber (2017) | RDL Network
IK channel activation increases tumor growth and induces differential behavioral responses in two breast epithelial cell lines
Article 2017 en
Authors
AT
Amy E. Thurber
MN
Michaela Nelson
CF
Crystal L. Frost
Abstract
1 min read
Many potassium channel families are over-expressed in cancer, but their mechanistic role in disease progression is poorly understood. Potassium channels modulate membrane potential (Vmem) and thereby influence calcium ion dynamics and other voltage-sensitive signaling mechanisms, potentially acting as transcriptional regulators. This study investigated the differential response to over-expression and activation of a cancer-associated potassium channel, the intermediate conductance calcium-activated potassium channel (IK), on aggressive behaviors in mammary epithelial and breast cancer cell lines. IK was over-expressed in the highly metastatic breast cancer cell line MDA-MB-231 and the spontaneously immortalized breast epithelial cell line MCF-10A, and the effect on cancer-associated behaviors was assessed. IK over-expression increased primary tumor growth and metastasis of MDA-MB-231 in orthotopic xenografts, demonstrating for the first time in any cancer type that increased IK is sufficient to promote cancer aggression. The primary tumors had similar vascularization as determined by CD31 staining and similar histological characteristics. Interestingly, despite the increased in vivo growth and metastasis, neither IK over-expression nor activation with agonist had a significant effect on MDA-MB-231 proliferation, invasion, or migration in vitro. In contrast, IK decreased MCF-10A proliferation and invasion through Matrigel but had no effect on migration in a scratch-wound assay. We conclude that IK activity is sufficient to promote cell aggression in vivo. Our data provide novel evidence supporting IK and downstream signaling networks as potential targets for cancer therapies.
Michael Rose, Vera Kloten, Erik Noetzel, Lukas Gola, Josef Ehling, Timon Heide, Steffen K. Meurer, Aljona Gaiko-Shcherbak, Antonio Sechi, Sebastian Huth, Ralf Weiskirchen, Oliver Klaas, Wiebke Antonopoulos, Qiong Lin, Wolfgang Wagner, Jürgen Veeck, Felix Gremse, Julia Steitz, Ruth Knüchel, Edgar Dahl
Discussion(0)
No comments yet. Be the first to comment.